Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: A systematic review

The Lancet Oncology

Volumn 16, Issue 1, 2015, Pages e23-e31

  Markar, Sheraz R ^a   Wiggins, Tom ^a   Ni, Melody ^a   Steyerberg, Ewout W ^b   Van Lanschot, J Jan B ^b   Sasako, Mitsuru ^c   Hanna, George B ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMORADIOTHERAPY; BURSECTOMY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; ESOPHAGUS SURGERY; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; MINIMALLY INVASIVE SURGERY; MORTALITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARDIZATION; STOMACH CANCER; STOMACH SURGERY; SURGEON; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ACCREDITATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CLINICAL COMPETENCE; ESOPHAGEAL NEOPLASMS; GASTRECTOMY; HEALTH CARE QUALITY; METHODOLOGY; PATHOLOGY; STANDARDS; STOMACH NEOPLASMS; TOTAL QUALITY MANAGEMENT; TUMOR RECURRENCE;

CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CLINICAL COMPETENCE; CREDENTIALING; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; GASTRECTOMY; HOSPITAL MORTALITY; HUMANS; LYMPH NODE EXCISION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84926120299     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70419-X     Document Type: Review

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
3. Schulz KF, Chalmers I, Hayes RJ, Altman DG Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995, 273:408-412.
4. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928. the Cochrane Bias Methods Group, the Cochrane Statistical Methods Groupthe Cochrane Statistical Methods Group.
5. Bunt AM, Hermans J, Boon MC, et al. Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer. J Clin Oncol 1994, 12:417-422.
6. Macdonald JS, Benedetti N, Estes N, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of intergroup study INT-0116 (SWOG 9008). Paper Presented at: 2004 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA, USA.
7. Foster JD, Mackenzie H, Nelson H, Hanna GB, Francis NK Methods of quality assurance in multicentre trials in laparoscopic colorectal surgery: a systematic review. Ann Surg 2014, 260:220-229.
8. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol 2003, 21:4592-4596. the Japan Clinical Oncology Group.
9. Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997, 114:205-209.
10. Bajetta E, Buzzoni R, Mariani L, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002, 13:299-307.
11. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012, 379:315-321. the CLASSIC trial investigators.
12. Bouché O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005, 16:1488-1497. the Fédération Francophone de Cancérologie Digestive Group.
13. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 2008, 100:388-398. the Italian Oncology Group for Cancer Research.
14. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
15. Miyashiro I, Furukawa H, Sasako M, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer 2011, 14:212-218. the Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group.
16. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet 1999, 354:273-277. the Gastric Cancer Surgical Study Group.
17. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007, 94:1468-1476. the National Surgical Adjuvant Study of Gastric Cancer Group.
18. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003, 21:2282-2287. the Gastric Cancer Surgical Study Group, Japan Clinical Oncology GroupJapan Clinical Oncology Group.
19. Nitti D, Wils J, Dos Santos JG, et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006, 17:262-269. the EORTC GI Group, the ICCGthe ICCG.
20. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011, 29:4387-4393.
21. Teoh AYB, Chiu PWY, Yeung WK, Liu SY, Wong SK, Ng EK Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol 2013, 24:165-171.
22. Chiu PWY, Chan ACW, Leung SF, et al. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005, 9:794-802.
23. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20. the MAGIC Trial Participants.
24. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062-5067.
25. Boonstra JJ, Kok TC, Wijnhoven BP, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 2011, 11:181.
26. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005, 6:659-668. the Trans-Tasman Radiation Oncology Group, the Australasian Gastro-Intestinal Trials Groupthe Australasian Gastro-Intestinal Trials Group.
27. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007, 25:3719-3725. the Radiation Therapy Oncology Group, the USA Intergroupthe USA Intergroup.
28. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010, 28:5210-5218.
29. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011, 29:1715-1721.
30. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008, 26:1086-1092.
31. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084. the CROSS Group.
32. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999, 340:908-914. the Dutch Gastric Cancer Group.
33. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008, 359:453-462. the Japan Clinical Oncology Group.
34. Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014, 101:23-31. the Italian Gastric Cancer Study Group.
35. Yonemura Y, Wu CC, Fukushima N, et al. Randomized clinical trial of D2 and extended para-aortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008, 13:132-137. the East Asia Surgical Oncology Group.
36. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007, 193:10-15. the Polish Gastric Cancer Study Group.
37. Imamura H, Kurokawa Y, Kawada J, et al. Influence of bursectomy on operative morbidity and mortality after radical gastrectomy for gastric cancer: results of a randomized controlled trial. World J Surg 2011, 35:625-630.
38. Omloo JMT, Lagarde SM, Hulscher JBF, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007, 246:992-1000.
39. Sasako M, Sano T, Yamamoto S, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006, 7:644-651. the Japan Clinical Oncology Group (JCOG9502).
40. Biere SSAY, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012, 379:1887-1892.
41. Sasako M, Kurokawa Y Challenges in performing surgical randomized controlled trials in Japan. Surgery 2009, 145:598-602.
42. Hanna GB, Amygdalos I, Ni M, et al. Improving the standard of lymph node retrieval after gastric cancer surgery. Histopathology 2013, 63:316-324.
43. Miskovic D, Ni M, Wyles SM, et al. Is competency assessment at the specialist level achievable? A study for the national training programme in laparoscopic colorectal surgery in England. Ann Surg 2013, 257:476-482. the National Training Programme in Laparoscopic Colorectal Surgery in England.
44. Suzuki H, Gotoda T, Sasako M, Saito D Detection of early gastric cancer: misunderstanding the role of mass screening. Gastric Cancer 2006, 9:315-319.
45. Cuschieri SA, Hanna GB Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma: let us move on to another era. Ann Surg 2014, 259:e90.